Literature DB >> 12169779

Malignant struma ovarii: report of a case and review of the literature.

I Kostoglou-Athanassiou1, I Lekka-Katsouli, L Gogou, L Papagrigoriou, I Chatonides, P Kaldrymides.   

Abstract

Malignant struma ovarii is a very rare disease and therefore there is neither common agreement on treatment regimens nor sufficient follow-up experience. The case of a 38-year-old woman with malignant struma ovarii is described. The patient presented with a clinically silent ovarian neoplasm discovered incidentally during investigations for metrorrhagia. The ovarian mass was resected and the tumor was found to be a teratoma. Within the teratoma a papillary thyroid carcinoma of the follicular variant was found. Subsequently, in order to make follow-up of the patient possible by thyroglobulin measurement and radioiodine whole body scintigraphy, near-total thyroidectomy was performed and the thyroid was found to be normal on histology. Whole body radioiodine scintigraphy with (131)I and ablation of the thyroid remnant by the administration of 80 mCi (131)I was performed. The patient recovered uneventfully and is now well. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12169779     DOI: 10.1159/000063215

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  4 in total

1.  Pulmonary papillary adenoma-like tumour arising in ovarian teratoma.

Authors:  Stefania Damiani
Journal:  Virchows Arch       Date:  2004-05-13       Impact factor: 4.064

2.  A case of papillary thyroid carcinoma in struma ovarii and review of the literature.

Authors:  W D Salman; Mayuri Singh; Z Twaij
Journal:  Patholog Res Int       Date:  2010-08-02

3.  Struma ovarii and peritoneal strumosis during pregnancy.

Authors:  Zheng Li; Jingxue Wang; Qian Chen
Journal:  BMC Pregnancy Childbirth       Date:  2021-05-02       Impact factor: 3.105

4.  Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary.

Authors:  Sijian Li; Tengyu Yang; Yang Xiang; Xiaoyan Li; Limeng Zhang; Shan Deng
Journal:  BMC Cancer       Date:  2021-04-09       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.